NP/PA Connect

News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|December 5, 2024

Efficacy and Safety of Current Treatments for HS

Author(s)Merrick D. Elias, DO, FAAD, Hadar Avihai Lev-Tov, MD, Iltefat Hamzavi, MD

Key Takeaways

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Episodes in this series

3 experts in this video

EP. 1 Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges

3 experts in this video

EP. 2 Efficacy and Safety of Current Treatments for HS

3 experts in this video

EP. 3 Future Innovations for HS Diagnosis and Management

3 experts in this video

EP. 4 Dosing Considerations and Assessing the Efficacy of Treatment

3 experts in this video

EP. 5 Potential Role of AI in HS Diagnosis

2 experts in this video

EP. 6 Early Recognition and Use of Biologics to Manage Hidradenitis Suppurativa

2 experts in this video

EP. 7 Setting Patient Expectations and Use of Combination Treatment for Hidradenitis Suppurativa

2 experts in this video

EP. 8 Treatment Switches and the Future of Hidradenitis Suppurativa Management

EP. 9 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 1

EP. 9 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 1

EP. 10 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 2

EP. 10 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 2

EP. 11 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3

EP. 11 Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Off-Label Case Series: Topical Roflumilast for Mild HS

ByMaddi Hebebrand, MC, Associate Editor

January 15th 2026

Timing, Severity, and Therapeutic Choice in Moderate to Severe HS

ByMaddi Hebebrand, MC, Associate Editor

January 14th 2026

Proactive Care for Kids: Why Maintenance Matters

ByAdam Friedman, MD, FAAD,Lawrence Eichenfield, MD,Alexandra K. Golant, MD

January 14th 2026

Safety and Efficacy of Roflumilast Cream for Pediatric Atopic Dermatitis

ByAdam Friedman, MD, FAAD,Lawrence Eichenfield, MD,Alexandra K. Golant, MD

January 14th 2026

Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001

ByMaddi Hebebrand, MC, Associate Editor

January 12th 2026

Latest CME

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Derm Nexus The Inflammatory Disease and Innovations Congress for NP/PAs

In-Person Event

Derm Nexus The Inflammatory Disease and Innovations Congress for NP/PAs

November 19-21, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications

Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors

Utilizing CYP2C9 Testing and JAK Inhibitors for Alopecia Areata

Timing, Severity, and Therapeutic Choice in Moderate to Severe HS

Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials